GCK and Hypoglycemia: Given the widespread implementation of fasting, the targeting of pathways through which liver glycogen content can be increased under these conditions (e.g., liver-specific glucokinase activators) could prove to be a viable target to enhance metabolic flexibility during hypoglycemia in vulnerable populations, such as those with type 1 diabetes.